Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Shares Reach All-Time High; Sequenom Hits 52-week High

NEW YORK (GenomeWeb News) – Shares of Illumina reached an all-time high of $91.41 in Wednesday trade on the Nasdaq before pulling back slightly to close at $90.10.
Meanwhile, Sequenom's shares hit a 52-week high of $17.52 during Wednesday trade, also on the Nasdaq, before closing at $17.37.
Illumina’s shares have been rising steadily over the past few weeks in advance of its second-quarter results being released later this month.
The firm has said that it expects to report second-quarter revenues of $127 million to $132 million with earnings per share of $.37 to $.40, which is above the consensus forecast from analysts of $.28 per share. For fiscal 2008, the firm expects to bring in revenues of between $515 million and $535 million.
Sequenom's stock is trading at a level not seen since early 2001. The company said earlier today that the underwriters of its recently completed public offering of common stock have exercised an option to acquire an additional 825,000 shares. It raised net proceeds of $92 million in the offering.
Sequenom's shares have risen sharply over the past month after it said that a blinded study showed that its molecular test for Down syndrome correctly identified 100 percent of all Down syndrome samples without any false-positive outcomes.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.